Let’s get into the actual science behind GLP-1 medications. Knowledge is power.
The Incretin System
Your body naturally produces incretin hormones after eating:
- GLP-1 (Glucagon-Like Peptide-1)
- GIP (Glucose-dependent Insulinotropic Polypeptide)
These hormones:
- Stimulate insulin secretion
- Suppress glucagon
- Slow gastric emptying
- Signal satiety to the brain
How GLP-1 RAs Work
GLP-1 Receptor Agonists (RAs) mimic natural GLP-1 but:
- Last much longer (days vs minutes)
- More potent activation
- Resistant to DPP-4 enzyme breakdown
- Consistent blood levels
The Brain Connection
GLP-1 receptors are found in:
- Hypothalamus - Appetite regulation
- Brainstem - Nausea center (explains side effects)
- Reward centers - May reduce “food noise”
This is why effects go beyond just slowing digestion.
Semaglutide vs Tirzepatide: Molecular Differences
Semaglutide
- Pure GLP-1 receptor agonist
- Modified to resist DPP-4
- Albumin binding extends half-life
- ~7 day half-life
Tirzepatide
- Dual GIP/GLP-1 agonist
- Activates both incretin pathways
- GIP component may add metabolic benefits
- Potentially different side effect profile
Key Clinical Trials
STEP Trials (Semaglutide)
- STEP 1: ~15% body weight loss at 68 weeks
- STEP 2-8: Various populations studied
- Cardiovascular benefits in SELECT trial
SURMOUNT Trials (Tirzepatide)
- SURMOUNT-1: ~20%+ body weight loss
- Significant A1C reductions
- Ongoing cardiovascular studies
For the actual studies: PubMed and ClinicalTrials.gov
Emerging Research
Areas being studied:
- Alzheimer’s disease
- NASH/fatty liver
- Sleep apnea
- Addiction
- Kidney disease
What We Don’t Know Yet
- Very long-term effects (10+ years)
- Optimal treatment duration
- Best maintenance strategies
- Full scope of off-target effects
The Importance of Medical Oversight
This science is complex. Working with knowledgeable providers ensures:
- Proper monitoring
- Evidence-based decisions
- Safety first approach
- Personalized care
What science questions do you have? Let’s dive deeper!